Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes

• Status: Completed
• Trial end date: 2003-04-24
• Target enrollment: 0
• Participant gender: All

Summary

This this trial is conducted in Europe. The aim of this trial is to compare glycaemic control of biphasic insulin aspart 30 (BIAsp 30) alone or combined with insulin aspart(IAsp) in patients previously treated with conventional Biphasic Human Insulin 30/70.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Biphasic Insulins; Insulin; Insulin Aspart; Insulin aspart, insulin aspart protamine drug combination 30:70; Insulin degludec, insulin aspart drug combination; Insulin, Globin Zinc; Insulin, Isophane; Insulin, Long-Acting

Criteria

Inclusion Criteria:

• Type 2 diabetes

• Current treatment with conventional biphasic human insulin 30/70 b.i.d. (twice daily) for at least 3 months

• HbA1c (glycosylated haemoglobin) equal to or below 12%

• Willing and able to perform self blood glucose monitoring (SMBG)

Exclusion Criteria:

• History of drug or alcohol dependence

• Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation

• Previous participation in this trial

• Receipt of any investigational drug within the last month prior to this trial

• Known or suspected allergy to trial products or related products